756 related articles for article (PubMed ID: 25496490)
21. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
Dimitroulis IA
Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
[TBL] [Abstract][Full Text] [Related]
22. Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis.
MacKenzie B; Korfei M; Henneke I; Sibinska Z; Tian X; Hezel S; Dilai S; Wasnick R; Schneider B; Wilhelm J; El Agha E; Klepetko W; Seeger W; Schermuly R; Günther A; Bellusci S
Respir Res; 2015 Jul; 16(1):83. PubMed ID: 26138239
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib.
Lin T; Gong L
Drug Des Devel Ther; 2017; 11():1147-1158. PubMed ID: 28435226
[TBL] [Abstract][Full Text] [Related]
24. Nintedanib: from discovery to the clinic.
Roth GJ; Binder R; Colbatzky F; Dallinger C; Schlenker-Herceg R; Hilberg F; Wollin SL; Kaiser R
J Med Chem; 2015 Feb; 58(3):1053-63. PubMed ID: 25474320
[TBL] [Abstract][Full Text] [Related]
25. Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice.
Huang X; Wang W; Yuan H; Sun J; Li L; Wu X; Luo J; Gu Y
Tohoku J Exp Med; 2016 Aug; 239(4):251-61. PubMed ID: 27439438
[TBL] [Abstract][Full Text] [Related]
26. Effects of basic fibroblast factor (bFGF) on MMP-2, TIMP-2, and type-I collagen levels in human lung carcinoma fibroblasts.
Nakoman C; Resmi H; Ay O; Acikel U; Atabey N; Güner G
Biochimie; 2005; 87(3-4):343-51. PubMed ID: 15781321
[TBL] [Abstract][Full Text] [Related]
27. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.
Lehtonen ST; Veijola A; Karvonen H; Lappi-Blanco E; Sormunen R; Korpela S; Zagai U; Sköld MC; Kaarteenaho R
Respir Res; 2016 Feb; 17():14. PubMed ID: 26846335
[TBL] [Abstract][Full Text] [Related]
28. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.
Huang J; Maier C; Zhang Y; Soare A; Dees C; Beyer C; Harre U; Chen CW; Distler O; Schett G; Wollin L; Distler JHW
Ann Rheum Dis; 2017 Nov; 76(11):1941-1948. PubMed ID: 28814429
[TBL] [Abstract][Full Text] [Related]
29. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
30. Prolonged Scar-in-a-Jar: an in vitro screening tool for anti-fibrotic therapies using biomarkers of extracellular matrix synthesis.
Rønnow SR; Dabbagh RQ; Genovese F; Nanthakumar CB; Barrett VJ; Good RB; Brockbank S; Cruwys S; Jessen H; Sorensen GL; Karsdal MA; Leeming DJ; Sand JMB
Respir Res; 2020 May; 21(1):108. PubMed ID: 32381012
[TBL] [Abstract][Full Text] [Related]
31. Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib.
Woodcock HV; Molyneaux PL; Maher TM
Drug Des Devel Ther; 2013; 7():503-10. PubMed ID: 23818761
[TBL] [Abstract][Full Text] [Related]
32. Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
Epstein Shochet G; Israeli-Shani L; Koslow M; Shitrit D
Lung Cancer; 2016 Jun; 96():7-14. PubMed ID: 27133742
[TBL] [Abstract][Full Text] [Related]
33. Effect of heparin and related glycosaminoglycan on PDGF-induced lung fibroblast proliferation, chemotactic response and matrix metalloproteinases activity.
Sasaki M; Kashima M; Ito T; Watanabe A; Sano M; Kagaya M; Shioya T; Miura M
Mediators Inflamm; 2000; 9(2):85-91. PubMed ID: 10958381
[TBL] [Abstract][Full Text] [Related]
34. Vardenafil Activity in Lung Fibrosis and In Vitro Synergy with Nintedanib.
Bourne MH; Kottom TJ; Hebrink DM; Choudhury M; Leof EB; Limper AH
Cells; 2021 Dec; 10(12):. PubMed ID: 34944010
[TBL] [Abstract][Full Text] [Related]
35. Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis.
Fukihara J; Kondoh Y
Expert Rev Respir Med; 2016 Dec; 10(12):1247-1254. PubMed ID: 27744713
[TBL] [Abstract][Full Text] [Related]
36. FGF9 and FGF18 in idiopathic pulmonary fibrosis promote survival and migration and inhibit myofibroblast differentiation of human lung fibroblasts in vitro.
Joannes A; Brayer S; Besnard V; Marchal-Sommé J; Jaillet M; Mordant P; Mal H; Borie R; Crestani B; Mailleux AA
Am J Physiol Lung Cell Mol Physiol; 2016 Apr; 310(7):L615-29. PubMed ID: 26773067
[TBL] [Abstract][Full Text] [Related]
37. Nintedanib-induced glomerular microangiopathy: a case report.
Hasegawa M; Uehara A; Suzuki T; Sekine R; Yazawa M; Ichikawa D; Koike J; Shibagaki Y
CEN Case Rep; 2020 Nov; 9(4):295-300. PubMed ID: 32279192
[TBL] [Abstract][Full Text] [Related]
38. Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease.
Atanelishvili I; Akter T; Noguchi A; Vuyiv O; Wollin L; Silver RM; Bogatkevich GS
Clin Exp Rheumatol; 2019; 37 Suppl 119(4):115-124. PubMed ID: 31573469
[TBL] [Abstract][Full Text] [Related]
39. Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs).
Joannes A; Voisin T; Morzadec C; Letellier A; Gutierrez FL; Chiforeanu DC; Le Naoures C; Guillot S; De Latour BR; Rouze S; Jaillet M; Crestani B; Wollin L; Jouneau S; Vernhet L
Pulm Pharmacol Ther; 2023 Dec; 83():102267. PubMed ID: 37972706
[TBL] [Abstract][Full Text] [Related]
40. Nintedanib inhibits keloid fibroblast functions by blocking the phosphorylation of multiple kinases and enhancing receptor internalization.
Zhou BY; Wang WB; Wu XL; Zhang WJ; Zhou GD; Gao Z; Liu W
Acta Pharmacol Sin; 2020 Sep; 41(9):1234-1245. PubMed ID: 32327724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
